Trial
NCT01484041
Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Georgetown University
Collaborators
Novartis Pharmaceuticals
Condition
Breast Cancer
Intervention
Dovitinib
Why stopped
Decision by company to cease development of dovitinib
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-02-09